Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Bromouracil SCHEMBL28990994 | 0.82 | DPYD (0.51) | DPYD | |
| SCHEMBL28928674 | 0.82 | CHUK (0.32) | CHUK | |
| SCHEMBL3825045 | 0.80 | CHUK (0.45) | DPYDCHUK | |
| SCHEMBL21295321 | 0.74 | KDM4E (0.31) | — | |
| SCHEMBL5822570 | 0.73 | TLR7 (0.31) | — | |
| SCHEMBL8676844 | 0.73 | PTPN11 (0.37) | — | |
| SCHEMBL3485208 | 0.73 | TLR8 (0.34) | — | |
| SCHEMBL2043792 | 0.72 | — | — | |
| SCHEMBL5143009 | 0.72 | — | — | |
| SCHEMBL4606082 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713485-A2 | SEQUENCING ADAPTERS FOR METHYLATION SEQUENCING | Foundation Medicine, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20250320496-A1 | MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-10-16 | — | — | US | claimed |
| EP-4627084-A1 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | Camp4 Therapeutics Corporation (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250290072-A1 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-09-18 | — | — | US | claimed |
| US-20250250575-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-08-07 | — | — | US | claimed |
| US-20250243488-A1 | METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-07-31 | — | — | US | claimed |
| WO-2024119145-A9 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-19 | — | — | WO | claimed |
| EP-4536831-A2 | METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | Camp4 Therapeutics Corporation (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119731320-A | Methods of modulating expression of granulin precursors using antisense oligonucleotides targeted to regulatory RNAs | 4阵营疗法公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2024238523-A2 | SEQUENCING ADAPTERS FOR METHYLATION SEQUENCING | FOUNDATION MEDICINE, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2016154040-A2 | BIOSYNTHETIC LABELING AND SEPARATION OF RNA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-29 | — | — | WO | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DPYD 250/4885CHUK 4667/4885 |
| US-20250320496-A1 | MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | ABCB11, SLC10A1, SREBF1 | DPYD 2772/4885CHUK 673/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DPYD 250/4885CHUK 4667/4885 |
| US-20250250575-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | DPYD 1073/4885CHUK 1191/4885 |
| US-20250243488-A1 | METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | GRN, SNRPE, UPF1 | DPYD 2827/4885CHUK 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.